Chlordiazepoxide Hydrochloride And Clidinium Bromide
Product Images NDC 70700-185

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Chlordiazepoxide Hydrochloride And Clidinium Bromide (NDC 70700-185). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chlordiazepoxide (Chlordiazepoxide)

HCI stands for Human-Computer Interaction. It refers to the study of designing, evaluating, and implementing interactive computing systems for human use and how humans interact with digital technology. This includes the study of user experience, usability, user interface design, and accessibility. The goal of HCI is to provide efficient and effective interfaces between humans and computers, improving users' experience and productivity.*

FDA Label Image

Clidinium (Clidinium)

FDA Label Image

Label (Label)

This is a description of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules. Each capsule contains 5mg of Chlordiazepoxide HCI USP and 2.5mg of Clidinium Bromide USP. The recommended dosage is one or two capsules 3 or 4 times a day, before meals and at bedtime, for adults. The medication guide should be dispensed to each patient. The capsules should be stored at 25°C (77°F) with excursions permitted to 15° to 30 °C (59° to 86°F) in a tight, light-resistant container as defined in the USP/NF. It is RxOnly and manufactured by Xiromed, LLC.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.